Tenders

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Tiotropium Olodaterol, Atc R03al06 for the Period June 1St, 2024 - May 31St, 2026

Open House Drug Discount Agreements Alitretinoin, Atc D11ah04

Open House Drug Discount Agreements Interferon Beta-1A, Finished Drug Name Avonex, Atc L03ab07

Open House Drug Discount Agreements Doravirine, Atc J05ag06

Staffing in the Social Security Field

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Tafluprost (S01ee05) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredients Timolol and Brinzolamide (S01ed67) as Part of a So-Called Open House Model.

Open House Drug Discount Agreements Vilanterol and Umeclidinium Bromide, Atc R03al03

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Melatonin (N05ch01), Excluding Prolonged-Release Tablets with an Effective Strength of 2Mg...

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Ciclosporin (S01xa18) as Part of a So-Called Open House Model.